Sort
48,018 grants matching “immunotherapy”
Expression of recombinant Fc receptors by engineered NK cells to enhance cancer cell killing
$431,818Bruce K Walcheck · University Of Minnesota · R01 · FY2023 · CA
Expression of recombinant Fc receptors by engineered NK cells to enhance cancer cell killing
$431,814Bruce K Walcheck · University Of Minnesota · R01 · FY2022 · CA
Metabolic Barriers to T Cell Activation in Clear Cell Renal Cell Carcinoma
$431,810Jeffrey C Rathmell · Vanderbilt University Medical Center · R01 · FY2019 · CA
Tau Oligomeric Complex 1 Antibody as a Novel Immuno-Gene Therapy for Tauopathy.
$431,750Nicholas M Kanaan · Henry Ford Health + Michigan State University Health Sciences · R21 · FY2024 · AG
Development and Validation of a Novel Anti-Pathogenic Tau Conformation (TNT2) scFv Immuno-Gene Therapy
$431,750Nicholas M Kanaan · Henry Ford Health + Michigan State University Health Sciences · R21 · FY2024 · AG
A Novel Adenoviral-Permissive, Immunocompetent Hamster Model to Evaluate Oncolytic Adenoviral Therapy for Glioblastoma
$431,749Frederick F Lang · University Of Tx Md Anderson Can Ctr · R01 · FY2024 · CA
NGTC - UCL
$431,742Martin Pule · University College London · OT2 · FY2023 · CA
Comprehensive identification of germline-somatic interactions
$431,738Hannah Kathryn Carter · University Of California, San Diego · R01 · FY2025 · CA
Cancer Stem Cells in Cholangiocarcinoma
$431,712Changqing Xie · Division Of Basic Sciences - Nci · ZIA · FY2024 · CA
Collagen Binding MSCRAMMs
$431,695Texas A&M University Health Science Ctr · R01 · FY2004 · AR
Exploiting the immunomodulatory effects of sulindac and novel non-COX inhibitory derivatives for cancer treatment
$431,691Gang Zhou · Augusta University · R01 · FY2021 · CA
A Mouse Model to Assess Long Term Immunotherapy-related Adverse Effects in Children
$431,631Pan Zheng · University Of Maryland Baltimore · R01 · FY2018 · CA
Targeting colorectal cancer stem cells with ALDH1B1 antagonists
$431,617James K Chen · Stanford University · R01 · FY2022 · CA
Role of IL-17+ Autoreactive T Cells in Experimental Autoimmune Uveitis (EAU)
$431,612Deming Sun · Doheny Eye Institute · R01 · FY2017 · EY
Role of IL-17+ Autoreactive T Cells in Experimental Autoimmune Uveitis (EAU)
$431,612Deming Sun · Doheny Eye Institute · R01 · FY2016 · EY
Role of IL-17+ Autoreactive T Cells in Experimental Autoimmune Uveitis (EAU)
$431,612Deming Sun · Doheny Eye Institute · R01 · FY2015 · EY
Targeting HMGA1 Tumor-Stromal Networks in Pancreatic Carcinogenesis
$431,561Linda M S Resar · Johns Hopkins University · R01 · FY2024 · CA
Impact of IFN-gamma on Neural Stem Cell Repair Potential in EAE
$431,555Samia J. Khoury · Brigham And Women'S Hospital · R01 · FY2009 · AI
Identifying and engaging a universal adjuvant for breaking macrophage immune tolerance in cancer
$431,501Mingye Feng · Beckman Research Institute/City Of Hope · R01 · FY2025 · CA
Identifying and engaging a universal adjuvant for breaking macrophage immune tolerance in cancer
$431,501Mingye Feng · Beckman Research Institute/City Of Hope · R01 · FY2021 · CA
Identifying and engaging a universal adjuvant for breaking macrophage immune tolerance in cancer
$431,501Mingye Feng · Beckman Research Institute/City Of Hope · R01 · FY2022 · CA
Biomaterials for Targeted Modulation of Conventional Type 1 Dendritic Cells
$431,451Hua Wang · University Of Illinois At Urbana-Champaign · R01 · FY2024 · CA
Probing cellular, molecular and biomechanical barriers to immunotherapy in the tumor microenvironment with organotypic in vitro models of the tumor-lympho-immune interface
$431,440Melody A Swartz · University Of Chicago · R01 · FY2022 · CA
Probing cellular, molecular and biomechanical barriers to immunotherapy in the tumor microenvironment with organotypic in vitro models of the tumor-lympho-immune interface
$431,440Melody A Swartz · University Of Chicago · R01 · FY2023 · CA
Pre-clinical testing of a novel immunotherapy for HTLV-induced neurologic disease
$431,433Pooja Jain · Drexel University · R01 · FY2020 · NS